Thermo Fisher Scientific Inc. — Q3 2019 Form 10-Q
Business context and period. The filing covers the quarter ended September 28, 2019, and the nine months then ended. Thermo Fisher supplies products and services to life sciences, analytical instruments, diagnostics, and laboratory markets through four reporting segments. Results are unaudited; interim results are not necessarily indicative of full-year performance.
Financial highlights
| Metric | Q3 2019 | Q3 2018 | Nine months 2019 | Nine months 2018 |
|---|---|---|---|---|
| Revenue | $6.272B | $5.920B | $18.713B | $17.851B |
| Operating income | $946M | $912M | $3.362B | $2.635B |
| Operating margin | 15.1% | 15.4% | 18.0% | 14.8% |
| Net income | $760M | $709M | $2.694B | $2.040B |
| Diluted EPS | $1.88 | $1.75 | $6.68 | $5.03 |
| Operating cash flow | Not separately presented | Not separately presented | $3.060B | $2.742B |
Margins and segment performance. Q3 revenue rose 6% reported and 7% excluding acquisition/divestiture and currency effects; operating income increased 4%, while consolidated margin declined 0.3 percentage points. Reportable-segment income rose 9%. Life Sciences Solutions revenue increased 13% and segment margin improved to 34.5%; Laboratory Products and Services revenue grew 6%, but margin fell to 11.6%. Specialty Diagnostics revenue declined 2%, reflecting the Anatomical Pathology divestiture, while Analytical Instruments grew 2%.
Cash, liquidity, and debt. At September 28, cash and cash equivalents were $1.273B, working capital was $4.67B, and total borrowings at carrying value were $17.053B, including $683M of commercial paper. Long-term obligations were $16.392B. Nine-month operating cash flow increased to $3.060B; investing activities used $1.148B and financing activities used $2.604B. The company had a $2.50B revolving facility with no borrowings outstanding and approximately $80M of capacity reserved for letters of credit.
Material changes and notable items
- Q3 revenue growth reflected $408M of operational growth, partly offset by an $83M currency impact; acquisitions net of divestitures added $27M.
- Nine-month operating income included a roughly $482M pretax gain on the Anatomical Pathology business sale. The sale generated $1.13B net proceeds; Brammer Bio was acquired for approximately $1.67B cash.
- Nine-month reported operating margin rose to 18.0% from 14.8%, substantially reflecting the divestiture gain. Excluding that gain, the filing does not provide a directly comparable adjusted consolidated margin.
- Cash from operations improved year over year, although growth absorbed cash through receivables ($321M) and inventory ($449M). Capital expenditures were $637M for the nine-month period.
- In early Q4, the company issued approximately $5.6B net proceeds of senior notes to repay commercial paper and redeem specified debt. It incurred approximately $142M of additional early-extinguishment losses in October; this is subsequent to the quarter.
Outlook, risks, and contingencies
- Management expected a 2019 effective tax rate of 8%–11%, cash income-tax payments of $725M–$775M, and full-year capital expenditures net of disposals of approximately $925M–$975M. No revenue or EPS guidance is stated in the provided filing text.
- Management said cash, future operating cash flow, and available revolving credit should meet existing-business cash requirements for at least the next 24 months.
- As of November 1, the company had identified additional restructuring actions expected to result in approximately $80M of charges, primarily in 2019 and 2020. Further actions could be identified.
- Key disclosed risks include economic and customer-spending uncertainty, foreign exchange and trade/tariff exposure, competition and product-development demands, regulatory and quality requirements in pharma services, acquisition integration and impairment risk, cybersecurity and data privacy, and substantial debt. Currency translation reduced nine-month revenue by $395M.
- Environmental remediation liabilities were approximately $63M. Various lawsuits and claims remain pending; the company reported no material accruals for other pending matters beyond those disclosed, while noting an unfavorable outcome could materially affect results, financial position, or cash flows.
Important facts for investors to verify
- How much underlying revenue and earnings growth persists after separating the Anatomical Pathology gain, acquisition effects, divestiture effects, and currency impacts.
- Whether segment margins—particularly in Laboratory Products and Services and Specialty Diagnostics—recover as investments and portfolio changes evolve.
- The cash-flow and leverage impact of the Q4 refinancing, debt redemptions, associated losses, and subsequent $750M share repurchase.
- Whether the 2019 tax-rate, cash-tax, capital-spending, and restructuring expectations were achieved, and whether disclosed legal and environmental exposures change.